Humanin, Research Reference

Humanin is a 21-amino acid peptide encoded within the 16S ribosomal RNA region of the human mitochondrial genome, making it one of the few known mitochondrial-derived peptides (MDPs). Research has investigated Humanin for cytoprotective, neuroprotective, and metabolic properties. Circulating Humanin levels have been observed to decline with age and in states of insulin resistance, placing it within the active area of longevity and mitochondrial biology research.

Quick Reference

Overview

Humanin occupies a distinctive position in peptide research as one of only a small number of bioactive peptides encoded directly in the mitochondrial genome rather than in nuclear DNA. Alongside MOTS-c, it belongs to the emerging class known as mitochondrial-derived peptides (MDPs), a category that has attracted considerable scientific attention for its potential links between mitochondrial function, cellular stress response, and systemic ageing.

Discovery

Humanin was identified in 2001 by Hashimoto and colleagues, reported in a landmark paper in the Proceedings of the National Academy of Sciences (PNAS). The discovery arose from a cDNA library screen designed to identify factors capable of protecting neuronal cells from death induced by familial Alzheimer’s disease (FAD)-related genes, including mutant forms of amyloid precursor protein (APP) and presenilin-1 and presenilin-2. The peptide was named “Humanin” by the original authors to reflect its identification in human brain tissue and the survival-promoting activity it conferred on neurons facing Alzheimer’s-associated apoptotic stimuli.

Mitochondrial Origin

Unlike the vast majority of peptides, which are encoded in nuclear DNA and translated in the cytoplasm, Humanin is encoded between the cytochrome b and tRNAThr genes in the mitochondrial 16S rRNA region. This origin is significant because it suggests Humanin may function as a mitochondrial stress-response signal, released when mitochondrial activity is perturbed and capable of communicating cellular status to tissues throughout the body. Circulating Humanin has been detected in human blood and has been measured at declining levels in older individuals and in individuals with metabolic disease, consistent with a role in the biology of age-related decline.

Mechanisms Investigated in Research

Research has characterised several mechanisms through which Humanin may exert its reported cytoprotective effects:

• Sequestration of BAX, a pro-apoptotic protein, reducing mitochondria-mediated programmed cell death
• Sequestration of IGFBP-3 (insulin-like growth factor binding protein 3), which has pro-apoptotic activity in certain contexts
• Activation of the JAK2/STAT3 signalling pathway, a pathway associated with cell survival and anti-inflammatory signalling
• Improved insulin sensitivity through mechanisms that remain under investigation in metabolic research
• Cytoprotection against oxidative stress and amyloid-beta peptide toxicity in neuronal models
• Binding to formyl peptide receptor-like 1 (FPRL1/FPR2) as a candidate cell-surface signalling receptor

Analogues

SHM-X (AGA-(C8R)-HNG17) is a synthetic analogue of native Humanin that has been investigated in preclinical models for greater neuroprotective potency relative to the native sequence. HNG (a related analogue with a serine-to-glycine substitution) is also reported in the preclinical literature. Human data for these analogues are not available as of 2026.

Reported Protocols

The following information represents commonly reported research ranges drawn from anecdotal accounts and available research literature. These are not medical recommendations.

The following protocol information is based on anecdotal community experience and publicly available research. It is not a medical recommendation. Dosages, frequencies, and routes described are reported ranges, not prescriptions. Individual responses vary. Use at your own risk.

Humanin is at an early stage of research relative to many other discussed peptides, and human pharmacokinetic data are limited. Dose ranges discussed in the research community are therefore less well anchored to controlled trial data than those for more clinically studied peptides. Commonly reported doses range from 1 mg to 4 mg per administration, with 1 mg to 2 mg representing the more conservative end of accounts encountered in the literature and anecdotal research discussions.

Subcutaneous Protocol

Subcutaneous injection is the most commonly reported administration route for Humanin in research and anecdotal accounts.

• Dose range: Commonly reported doses range from 1 mg to 2 mg per administration in the majority of accounts; some research contexts describe up to 4 mg
• Frequency: Anecdotal reports describe administration ranging from daily to three times per week; no established optimal frequency exists in the published human literature
• Cycle duration: Accounts describe cycles ranging from 4 to 12 weeks, reflecting the exploratory nature of research-stage use
• Injection site: Subcutaneous injection into the abdominal region is the most commonly described approach, with site rotation between administrations

Intranasal Protocol

Intranasal administration is discussed in some research accounts and may offer a route of relevance given Humanin’s investigated neuroprotective properties, as intranasal delivery can support transport along olfactory pathways toward the central nervous system.

• Dose range: Intranasal doses are less consistently described; accounts mention doses in the range of 1 mg to 2 mg per administration
• Frequency: Intranasal administration frequencies mirror those described for subcutaneous use in anecdotal accounts
• Note: Bioavailability via intranasal administration has not been systematically characterised for Humanin in published pharmacokinetic studies; the route is discussed on a theoretical and anecdotal basis

Notes on Dose Uncertainty

Given the early stage of Humanin research and the absence of human dose-finding trials, the dose ranges described here carry greater uncertainty than those for peptides with established clinical trial data. Anecdotal accounts should be interpreted with this context in mind.

Reported Effects

The following effects have been reported in preclinical research and anecdotal accounts. This list reflects the research landscape and does not constitute confirmed clinical outcomes for any specific individual. The majority of evidence cited below is derived from cell culture and animal studies; human clinical data remain limited as of 2026.

Cytoprotection and Anti-Apoptotic Activity

Research has most consistently characterised Humanin for cytoprotective effects in cellular and animal models:

• Inhibition of BAX-mediated mitochondrial apoptosis in neuronal and non-neuronal cell lines
• Protection against apoptotic stimuli associated with familial Alzheimer’s disease gene mutations in neuronal culture models
• Reduction of cell death induced by amyloid-beta peptide exposure in preclinical neuronal models
• Protective effects against oxidative stress in cell culture settings

Neuroprotection

Humanin’s original characterisation was in a neuroprotective context, and subsequent research has continued to investigate its effects on neuronal survival:

• Preclinical research has investigated Humanin for potential protective effects relevant to Alzheimer’s disease, with studies reporting reduced neuronal death in amyloid-beta-exposed cultures
• Animal model research has reported cognitive outcome improvements in some Alzheimer’s disease model studies
• Research has investigated Humanin in the context of neurodegeneration more broadly, including models relevant to Parkinson’s disease and ischaemic injury, though evidence in these areas is less developed than in the Alzheimer’s context

Metabolic and Insulin Sensitivity Effects

Research has investigated Humanin in metabolic contexts, with some studies reporting:

• Improved insulin sensitivity in animal models of insulin resistance
• Potential effects on glucose metabolism that parallel aspects of the research conducted on MOTS-c, the other well-characterised mitochondrial-derived peptide
• Associations between lower circulating Humanin levels and metabolic disease states in observational research

Cardiovascular Research

Some research has extended investigation of Humanin to cardiovascular contexts:

• Preclinical studies have reported potential cardioprotective effects, including reduced cardiomyocyte apoptosis in ischaemia models
• Research has investigated potential effects on atherosclerosis-relevant cellular processes in animal models
• The degree to which these preclinical findings translate to human cardiovascular outcomes is not established

Age-Related Decline and Longevity Research

The observation that circulating Humanin levels decline with age has positioned it within longevity research:

• Observational research has reported associations between higher circulating Humanin levels and improved metabolic and cognitive markers in older adults
• Research in centenarian cohorts and their offspring has identified higher Humanin levels in these groups compared with age-matched controls in some studies
• Preclinical lifespan data from animal models are limited and have not been replicated consistently across model organisms

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following. This list does not constitute a comprehensive safety profile and should not be interpreted as predictive of individual outcomes.

The human safety data for Humanin are substantially more limited than those available for peptides that have undergone formal clinical trials. Animal studies have generally reported a well-tolerated profile at doses investigated preclinically, but the translation of animal safety findings to human experience is not established. The majority of available human accounts are anecdotal, and systematic characterisation of adverse effects in controlled settings has not been conducted as of 2026.

Humanin is not reported to produce hormonal suppression or organ toxicity in preclinical models at doses typically studied. Given the absence of long-term human safety data, individuals participating in research with this compound should exercise appropriate caution.

Storage & Handling

Lyophilized Powder (Unreconstituted)

• Refrigerator (2-8°C): Preferred storage condition; commonly reported stable for 12 months or longer when stored properly in a sealed, opaque vial
• Freezer (-20°C): Suitable for longer-term storage of the dry powder; avoid repeated freeze-thaw cycles, which can degrade peptide integrity
• Room temperature: Not recommended for extended storage; brief exposure during handling is acceptable
• Light sensitivity: Store away from direct light exposure; amber or opaque vials are preferred

Reconstituted Solution

• Refrigerator (2-8°C): Required storage once reconstituted
• Bacteriostatic water: Recommended as the diluent for multi-dose vials; supports stability for up to 28 days when refrigerated
• Sterile water: May be used for single-dose reconstitution, though storage duration is shorter and same-day use is recommended
• Do not freeze a reconstituted solution; freezing may degrade peptide structure and compromise activity
• Discard if the solution becomes cloudy, discoloured, or shows particulate matter

Reconstitution

Add the chosen diluent slowly to the lyophilized vial, directing the liquid along the inside wall of the vial rather than directly onto the peptide cake. Swirl gently; do not shake. Allow several minutes for complete dissolution. See the Reconstitution Guide for step-by-step instructions.

Frequently Asked Questions

What makes Humanin a mitochondrial-derived peptide? Humanin is encoded not in the nuclear genome but within the 16S ribosomal RNA region of the mitochondrial genome, specifically between the cytochrome b and tRNAThr genes. This makes it part of a small and relatively recently characterised class known as mitochondrial-derived peptides (MDPs). Unlike the vast majority of peptides, which are encoded by nuclear DNA and translated in the cytoplasm, Humanin is translated within the mitochondrion itself and then secreted into circulation. This mitochondrial origin is thought to underlie its role as a stress-response signal: as mitochondrial function declines with age or under metabolic stress, circulating Humanin levels fall, potentially reducing cytoprotective signalling in tissues including the brain and vasculature.

How does Humanin differ from MOTS-c? Both Humanin and MOTS-c are mitochondrial-derived peptides (MDPs) encoded in the mitochondrial genome, but they differ substantially in sequence, size, and reported biological activity. Humanin is a 21-amino acid peptide encoded in the 16S rRNA region and is primarily characterised for neuroprotective and anti-apoptotic functions, including protection against amyloid-beta toxicity relevant to Alzheimer’s disease. MOTS-c is a 16-amino acid peptide encoded in the 12S rRNA region and is more prominently associated with metabolic regulation, including improved insulin sensitivity, exercise-like metabolic effects, and mitochondrial biogenesis. Research has investigated both peptides in the context of healthy ageing, but through distinct mechanistic pathways: Humanin acts partly via JAK2/STAT3 signalling and BAX sequestration, while MOTS-c acts more prominently through AMPK activation and modulation of the folate-methionine cycle.

What does the research say about Humanin and Alzheimer’s disease? Humanin was originally identified in 2001 by Hashimoto et al. in a screen specifically designed to find factors that protect neurons from Alzheimer’s-associated cell death. The original PNAS paper demonstrated that Humanin suppressed neuronal apoptosis induced by several familial Alzheimer’s disease (FAD) genes, including amyloid precursor protein (APP) mutants and presenilin-1 and presenilin-2 mutants. Subsequent preclinical research showed that Humanin reduces amyloid-beta toxicity in neuronal cell cultures and in animal models, at least in part by sequestering IGFBP-3 and inhibiting BAX-mediated apoptosis. Circulating Humanin levels have been reported to be lower in individuals with Alzheimer’s disease compared with age-matched controls in some observational studies. As of 2026, this evidence remains largely preclinical; controlled human clinical trials specifically investigating Humanin in Alzheimer’s disease have not been completed, and the translation from cell and animal models to human outcomes is not yet established.

What is the SHM-X analogue of Humanin? SHM-X, also referred to as AGA-(C8R)-HNG17, is a synthetic analogue of native Humanin engineered for greater potency and stability. It incorporates modifications at specific residue positions that increase its binding affinity and resistance to proteolytic degradation compared with the native 21-amino acid sequence. Preclinical studies have reported that SHM-X retains and in some models exceeds the neuroprotective and anti-apoptotic potency of native Humanin, including protection against amyloid-beta toxicity in neuronal cultures. Because SHM-X has not been studied in human clinical trials, its pharmacokinetics, safety profile, and effective dose ranges in humans are not established. Research accounts discussing Humanin analogues sometimes use SHM-X and HNG (a related analogue with a serine-to-glycine substitution) interchangeably, though they are distinct modifications.

Related Pages

Goals: Longevity | Neuroprotection | Cognitive Support

Class: Mitochondrial Peptides

Also see: MOTS-c (a related mitochondrial-derived peptide investigated primarily for metabolic regulation) | SS-31 (a mitochondria-targeting antioxidant peptide) | Epitalon (a tetrapeptide investigated in longevity and anti-ageing research)

References & Further Reading

• Hashimoto Y, et al. (2001). A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Abeta. Proceedings of the National Academy of Sciences, 98(11), 6336-6341. PubMed →
• Cobb LJ, et al. (2016). Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging, 8(4), 796-809. PubMed →
• Kim SJ, et al. (2018). Mitochondrially derived peptides as novel regulators of metabolism. Journal of Physiology, 595(21), 6613-6621. PubMed →
• Yen K, et al. (2020). The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging, 12(12), 11185-11199. PubMed →
• Lee C, et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 21(3), 443-454. PubMed →
• Muzumdar RH, et al. (2009). Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(10), 1940-1948. PubMed →
• Gong Z, et al. (2014). Humanin is an endogenous activator of chaperone-mediated autophagy. Journal of Cell Biology, 207(2), 235-246. PubMed →